Latest Breaking News On - Robert bitterman - Page 2 : comparemela.com

Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx s Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute

/PRNewswire/ Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is.

United statesBridge viewRobert bittermanBrendan curtiRobertw franzAndrew weinbergMichael adamsAshleyr robinsonClinical researchJoseph healthEarlea chiles research instituteProvidence cancer instituteProvidence cancer institute in portlandPrnewswire phio pharmaceuticals corpPhio pharmaceuticals corpProvidence cancer institute of oregon

Phio Pharmaceuticals (PHIO) Granted FDA Clearance to Initiate Trial of PH-762

Phio Pharmaceuticals (PHIO) Granted FDA Clearance to Initiate Trial of PH-762
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Robert bittermanMary spellmanAshleyr robinsonAgonox incDrug administrationContact phio pharmaceuticals corpCompany investigational new drugPhio pharmaceuticals corpWall streetInvestigational new drugActing chief medical officerPrivate securities litigation reform actAnnual report

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Mary spellmanRobert bittermanAshleyr robinsonCompany investigational new drugDrug administrationPhio pharmaceuticals corpAgonox incContact phio pharmaceuticals corpPhio pharmaceuticalsInvestigational new drugActing chief medical officerPrivate securities litigation reform actAnnual report

Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

/PRNewswire/ Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is.

United statesAshleyr robinsonRobert bittermanAmerican association for cancer researchDevelopment expensesAmerican society of genePhio pharmaceuticals corpContact phio pharmaceuticals corpPrnewswire phio pharmaceuticals corpPhio pharmaceutical presidentChief executiveAmerican associationCancer researchAnnual meetingAmerican societyCell therapy

Form 8-K Phio Pharmaceuticals For: Apr 18

Form 8-K Phio Pharmaceuticals For: Apr 18
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRobert bittermanPhio pharmaceuticals corpSecurities exchangeCommission file numberPhio pharmaceuticals presents preclinical data demonstrating synergyAmerican association for cancer researchZip codeGeneral instructionSecurities actExchange actSecurities exchange actPhio pharmaceuticalsAmerican associationCancer researchAnti tumor efficacy